1. Home
  2. SYNX vs CDT Comparison

SYNX vs CDT Comparison

Compare SYNX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$1.16

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.04

Market Cap

5.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYNX
CDT
Founded
2005
2019
Country
Israel
United States
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
5.9M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SYNX
CDT
Price
$1.16
$1.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
91.8K
75.3K
Earning Date
05-01-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$32.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.37
52 Week High
$2.15
$11.00

Technical Indicators

Market Signals
Indicator
SYNX
CDT
Relative Strength Index (RSI) 47.97 33.19
Support Level $0.93 $0.49
Resistance Level $1.34 $1.22
Average True Range (ATR) 0.07 0.22
MACD -0.01 -0.08
Stochastic Oscillator 40.00 4.85

Price Performance

Historical Comparison
SYNX
CDT

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

Share on Social Networks: